← Eichor
Condition: Neuroblastoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Neuroblastoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumo
Phase 1/Phase 2 · 71 location(s) · Merck Sharp & Dohme LLC · NCT06395103NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
Phase 2 · 13 location(s) · New Approaches to Neuroblastoma Therapy Consortium · NCT06450041Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation
EARLY_Phase 1 · 12 location(s) · C17 Council · NCT06942039Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biologica
Phase N/A · 5 location(s) · National Cancer Institute (NCI) · NCT01109394An International Study on Pediatric Patients With Rare Tumors.
Phase N/A · 1 location(s) · Azienda Ospedaliera di Padova · NCT07072143GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma
Phase 1 · 1 location(s) · Baylor College of Medicine · NCT03294954Chimeric Natural Killer Receptor-Universal T Cells for Relapsed or Refractory Neuroblastoma
Phase 1 · 2 location(s) · Nanjing Children's Hospital · NCT06751134A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT06041516A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Pat
Phase 2 · 4 location(s) · St. Jude Children's Research Hospital · NCT07085338Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory
Phase 1 · 2 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT03721068Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms
Phase N/A · 1 location(s) · National Cancer Institute (NCI) · NCT01005654Safety & Efficacy of IR-101 in Relapsed/Refractory Neuroblastoma
EARLY_Phase 1 · 2 location(s) · Sichuan University · NCT07067346Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Phase 1/Phase 2 · 2 location(s) · University of Arizona · NCT06814496Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
Phase 1 · 1 location(s) · Stanford University · NCT06500819A Multi-Arm, Platform Trial For Relapsed Neuroblastoma
Phase 1/Phase 2 · 23 location(s) · University of Birmingham · NCT07334301Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Phase 3 · 162 location(s) · Children's Oncology Group · NCT03126916High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)
Phase 3 · 126 location(s) · St. Anna Kinderkrebsforschung · NCT01704716Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome
Phase N/A · 1 location(s) · Memorial Sloan Kettering Cancer Center · NCT00588068Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma
Phase 1/Phase 2 · 2 location(s) · Roberto Chiarle · NCT06803875A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
Phase 2 · 6 location(s) · Nationwide Children's Hospital · NCT05135975NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Phase 1/Phase 2 · 1 location(s) · Nationwide Children's Hospital · NCT0421167518F-MFBG PET/CT in the Evaluation of Neural Crest Tumor
EARLY_Phase 1 · 1 location(s) · Peking Union Medical College Hospital · NCT0506922018F-mFBG PET Imaging in the Evaluation of Neuroblastoma
Phase N/A · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT06852807N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
Phase 2 · 1 location(s) · Memorial Sloan Kettering Cancer Center · NCT06528496Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Phase 1/Phase 2 · 22 location(s) · Milton S. Hershey Medical Center · NCT06541262A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
Phase 2 · 1 location(s) · Memorial Sloan Kettering Cancer Center · NCT0493652918F-mFBG LAFOV PET/CT Compared to 123I-mIBG Scintigraphy SPECT/CT for Evaluation of Children With Neuroblastoma
NA · 1 location(s) · Rigshospitalet, Denmark · NCT05826158International PPB/DICER1 Registry
Phase N/A · 1 location(s) · Children's Hospitals and Clinics of Minnesota · NCT03382158NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neurob
Phase 1 · 1 location(s) · Baylor College of Medicine · NCT07211737Indocyanine Green (ICG) Guided Tumor Resection
Phase 1 · 1 location(s) · St. Jude Children's Research Hospital · NCT04084067
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.